HOME Research Insight Major Players in the Human Microbiome Market Considered Agreements/Partnerships and Collaboration as the Key Strategy

Major Players in the Human Microbiome Market Considered Agreements/Partnerships and Collaboration as the Key Strategy

The key players in the human microbiome market are Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel, Inc. (U.S.), and Merck (U.S.). This is an emerging market, expected to be a highly niche one. Domination of the individual segments in this market will depend on the core competencies of different players.

Companies that launch products targeted at specific indications in the human microbiome market are likely to maintain their positions in this market. Pfizer is one such company; it releases medicines and vaccines for specific indications. The firm also entered into agreement with Second Genome for microbiome research in obesity and metabolic disorders.

Companies in the human microbiome market are majorly focusing on expanding and entering segments for new indications and technology. The key strategy is to expand market share through acquisitions and connect financially with firms having common values and goals. To gain maximum market share, companies have been aggressively signing agreements, collaborations, and partnerships with third-party vendors.

In-depth research into the human microbiome market revealed that agreements, partnerships, and collaborations were the key strategies adopted by major players to enter the microbiome business or expand their microbiome business units.

Major players that signed agreements, partnerships and entered into collaborations include Second Genome (U.S.), Enterome Bioscience (France), Vedanta Bioscience (U.S.), and Osel, Inc. (U.S.). Pfizer’s agreement in May 2014 with Second Genome will enable the former to study various new approaches for better treatment of metabolic diseases, such as diabetes. The agreement will also help Pfizer to capitalize on greater opportunities in the field of diabetes using microbiome-based anti-diabetes therapeutics.

Related Reports:

Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & by Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) – Global Forecast to 2023

Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support

US : 1-888-600-6441

Search reports